Annual Meeting Recap: Wednesday

Wednesday opened with an engaging Keynote Presentation by Dr. Christine Mummery from Leiden University on Cardiomyocytes from Human Pluripotent Stem Cells: The New Patient in Safety Pharmacology, Drug Discovery and Disease. 

Dr. Mummery discussed and presented data on derivation of heart cells from human pluripotent stem cells (hPSC) as a way to model disease phenotypes, and as a platform for drug discovery and toxicity. 

The SPS Business meeting, given by the SPS President Derek J. Leishman, followed. The future SPS Annual Meeting locations were revealed to be: Prague (2015), and Vancouver (2016). Dr.Leishman updated the membership on the current state of SPS, and informed the audience that the Board used a process called the Business Model Generation Canvas during their Face to Face meeting in Rotterdam to kick start the strategic planning process.

The membership will be updated and asked for input on the strategic plan in the near future, with the goal being to have a revised strategic plan by the New Year.

As a member of the Society, we encourage you to participate in our community and have your voice heard by becoming an active Committee Member. In order to volunteer for a Committee all you need to do is follow this link to sign up: https://www.safetypharmacology.org/volunteer.asp

 

Please note, an active membership is required to participate on Committees. If your membership will expire this year, be sure to keep an eye out for the upcoming dues renewal message and take appropriate action. 

 

 

 

1 Comment

Dr Mummery's talk

October 2, 2013 01:09 PM by Ken Gibson

Very disappointing that non-attendee members can not see/hear this presentation.

Recent Stories
SPS Webinar: Engineering Microscale Disease Models for Heart and Skeletal Muscle - June 11

SPS 2020 Annual Meeting: COVID-19 Update

Safety Pharm Chats – Connecting Outside the Bench